FDA approval process questioned as it approves new early-stage $56K US/year treatment for Alzheimer’s despite its own panel founding insufficient evidence of efficacy. Only when company changed the study endpoint did it show efficacy compared to placebo.
FDA approval process questioned as it approves new early-stage $56K US/year treatment for Alzheimer's despite its own panel founding insufficient evidence of efficacy. Only when company changed the study endpoint did it show efficacy compared to placebo.Play Now | Play in Popup | Download